2020
Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child–Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
Zu Q, Schenning RC, Jahangiri Y, Tomozawa Y, Kolbeck KJ, Kaufman JA, Al-Hakim R, Naugler WE, Nabavizadeh N, Kardosh A, Billingsley KG, Mayo SC, Orloff SL, Enestvedt KK, Maynard E, Ahn J, Lhewa D, Farsad K. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child–Pugh A Versus B7 Patients: Are the Outcomes Equivalent? CardioVascular And Interventional Radiology 2020, 43: 721-731. PMID: 32140840, DOI: 10.1007/s00270-020-02434-4.Peer-Reviewed Original ResearchConceptsC hepatocellular carcinomaChild-Pugh AAdvanced hepatocellular carcinomaOverall survivalHepatocellular carcinomaBCLC stage C hepatocellular carcinomaEastern Cooperative Oncology Group scoreBCLC-C hepatocellular carcinomasMultivariable Cox regression analysisChild-Pugh scoreMedian overall survivalChild-Pugh classKaplan-Meier methodCox regression analysisYttrium-90 RadioembolizationLog-rank testCautious patient selectionSignificant independent predictorsChild-PughHCV infectionResultsMean ageY90 radioembolizationAdditional malignanciesConsecutive patientsIndependent predictorsEffect of Time to Surgery of Colorectal Liver Metastases on Survival
Chen EY, Mayo SC, Sutton T, Kearney MR, Kardosh A, Vaccaro GM, Billingsley KG, Lopez CD. Effect of Time to Surgery of Colorectal Liver Metastases on Survival. Journal Of Gastrointestinal Cancer 2020, 52: 169-176. PMID: 32086781, PMCID: PMC7900034, DOI: 10.1007/s12029-020-00372-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColorectal NeoplasmsDisease-Free SurvivalFemaleFollow-Up StudiesHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRetrospective StudiesTime FactorsTime-to-TreatmentYoung AdultConceptsColorectal liver metastasesLong-term OSPostoperative overall survivalOverall survivalLonger TTSLiver metastasesWorse survivalDiagnosis of CLMLong-term survivorsResultsTwo hundred eightyRisk of recurrenceComprehensive cancer centerHigh disease burdenSpecific primary tumorsShorter TTSPerioperative chemotherapyPostoperative chemotherapyPerioperative treatmentResection marginsCancer CenterMetastasis characteristicsInstitutional databasePrimary tumorDisease burdenSimilar survival
2019
Who Undergoes Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Appendiceal Cancer? An Analysis of the National Cancer Database
Byrne RM, Gilbert EW, Dewey EN, Herzig DO, Lu KC, Billingsley KG, Deveney KE, Tsikitis VL. Who Undergoes Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Appendiceal Cancer? An Analysis of the National Cancer Database. Journal Of Surgical Research 2019, 238: 198-206. PMID: 30772678, DOI: 10.1016/j.jss.2019.01.039.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAppendiceal NeoplasmsChemotherapy, AdjuvantChemotherapy, Cancer, Regional PerfusionCytoreduction Surgical ProceduresDatabases, FactualFemaleHumansHyperthermia, InducedKaplan-Meier EstimateMaleMiddle AgedNeoadjuvant TherapyRetrospective StudiesSex FactorsTreatment OutcomeUnited StatesConceptsPerioperative intraperitoneal chemotherapyAppendiceal cancerCytoreductive surgeryIntraperitoneal chemotherapyTreatment modalitiesNational Cancer Database dataMultivariate logistic regression analysisNational Cancer DatabasePatterns of careLow-grade tumorsNon-Hispanic ethnicityLogistic regression analysisMucinous malignanciesSystemic chemotherapyMultimodality treatmentClinical factorsImproved survivalPatient selectionMale sexKaplan-MeierPatient cohortCancer DatabaseWhite raceTreatment groupsChemotherapy
2018
Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas
Lu E, Perlewitz KS, Hayden JB, Hung AY, Doung YC, Davis LE, Mansoor A, Vetto JT, Billingsley KG, Kaempf A, Park B, Ryan CW. Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas. Annals Of Surgical Oncology 2018, 25: 920-927. PMID: 29388122, DOI: 10.1245/s10434-018-6346-4.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasHigh-risk soft tissue sarcomasPhase II studyII studyPreoperative radiationTissue sarcomasHigh-grade soft tissue sarcomasHigh-risk STS patientsDistant disease-free survivalM2/dayExtensive institutional experienceLocal-regional failureDisease-free survivalRetrospective chart reviewDose-intense chemotherapyFavorable clinical outcomePercent of tumorsGy of radiationPostoperative cyclesTrimodality therapyPreoperative therapyWound complicationsChart reviewOverall survivalPathologic response
2017
Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713
Leichman CG, McDonough SL, Smalley SR, Billingsley KG, Lenz HJ, Beldner MA, Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS. Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. Clinical Colorectal Cancer 2017, 17: e121-e125. PMID: 29233486, PMCID: PMC6598683, DOI: 10.1016/j.clcc.2017.10.008.Peer-Reviewed Original ResearchConceptsPathologic complete responseAdvanced rectal cancerNeoadjuvant chemoradiationRectal cancerInduction chemotherapyKRAS wild-type metastatic colorectal cancerWild-type metastatic colorectal cancerThree-year disease-free survivalLocally Advanced Rectal CancerMetastatic colorectal cancerDisease-free survivalPhase III trialsAdequate hematologicEligible patientsBowel obstructionSame regimenIII trialsPerformance statusRenal functionComplete responseImproved survivalClinical outcomesMicroscopic cancerRectal adenocarcinomaPatient eligibility
2014
The international normalized ratio overestimates coagulopathy in patients after major hepatectomy
Louis S, Barton J, Riha G, Orloff S, Sheppard B, Pommier R, Underwood S, Differding J, Schreiber M, Billingsley K. The international normalized ratio overestimates coagulopathy in patients after major hepatectomy. The American Journal Of Surgery 2014, 207: 723-727. PMID: 24791634, DOI: 10.1016/j.amjsurg.2013.12.021.Peer-Reviewed Original ResearchConceptsInternational normalized ratioMajor hepatectomyNormalized ratioPatient populationElevated international normalized ratioUse of thrombelastographyPostoperative day 1Postoperative time pointsHypercoagulable statePreoperative valuesDecreased incidenceProcoagulant factorsTEG measurementsCoagulation factorsDay 1ThrombelastographyHepatectomyFactor VIIISubsequent normalizationPatientsTime pointsHypocoagulabilityTherapyProtein C.
2013
Safety and Outcomes Following Resection of Colorectal Liver Metastases in the Era of Current Perioperative Chemotherapy
Gur I, Diggs B, Wagner J, Vaccaro G, Lopez C, Sheppard B, Orloff S, Billingsley K. Safety and Outcomes Following Resection of Colorectal Liver Metastases in the Era of Current Perioperative Chemotherapy. Journal Of Gastrointestinal Surgery 2013, 17: 2133-2142. PMID: 24091909, DOI: 10.1007/s11605-013-2295-1.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesPreoperative chemotherapyPerioperative chemotherapyOverall survivalLiver metastasesAdvanced ageResectable colorectal liver metastasesPreoperative portal vein embolizationShorter disease-free intervalAcademic oncology centerOutcomes Following ResectionThirty-day mortalityDisease-free intervalHigh-risk patientsPortal vein embolizationSubset of patientsPoor overall survivalLiver recurrenceSynchronous diseaseEleven patientsPostoperative complicationsRepeat resectionLiver resectionVein embolizationRetrospective reviewCoagulopathy after a liver resection: is it over diagnosed and over treated?
Barton J, Riha G, Differding J, Underwood S, Curren J, Sheppard B, Pommier R, Orloff S, Schreiber M, Billingsley K. Coagulopathy after a liver resection: is it over diagnosed and over treated? Hepato Pancreato Biliary 2013, 15: 865-871. PMID: 23458574, PMCID: PMC4503284, DOI: 10.1111/hpb.12051.Peer-Reviewed Original ResearchConceptsProthrombin time-international normalized ratioPost-operative time pointsLiver resectionPost-operative day 1Initiation of thromboprophylaxisLiver resection patientsNormal coagulation functionTime pointsPT-INR valuesTime of onsetProphylactic anticoagulationElective hepatectomyResection patientsPlasma transfusionHypercoagulable stateAnesthetic techniqueCoagulation functionNormalized ratioPlasma therapyPringle manoeuverRelative hypercoagulabilityFunctional assessmentDay 1ResectionThrombelastography
2011
S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma
Leichman L, Goldman B, Bohanes P, Lenz H, Thomas C, Billingsley K, Corless C, Iqbal S, Gold P, Benedetti J, Danenberg K, Blanke C. S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2011, 29: 4555-4560. PMID: 22025151, PMCID: PMC3236655, DOI: 10.1200/jco.2011.36.7490.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDrug Administration ScheduleEsophageal NeoplasmsEsophagectomyFemaleFluorouracilHumansMaleMiddle AgedNeoadjuvant TherapyOrganoplatinum CompoundsOxaliplatinRadiotherapy, AdjuvantConceptsPathologic complete responseEsophageal adenocarcinomaOverall survivalNeoadjuvant therapyExternal beam radiation therapyPhase II ClinicalProspective exploratory analysisPatient underwent surgeryPrimary end pointProgression-free survivalSouthwest Oncology GroupAdvanced esophageal adenocarcinomaSingle-arm trialGy/dNeoadjuvant oxaliplatinSystemic regimenPreoperative therapyR0 resectionUnderwent surgeryOncology GroupPCR rateComplete responseImproved survivalFuture trialsGrade 3Predicting malignant intraductal papillary mucinous neoplasm: a single-center review
Cone M, Rea J, Diggs B, Douthit M, Billingsley K, Sheppard B. Predicting malignant intraductal papillary mucinous neoplasm: a single-center review. The American Journal Of Surgery 2011, 201: 575-579. PMID: 21545902, DOI: 10.1016/j.amjsurg.2011.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, MucinousAdultAgedAged, 80 and overCarcinoma, Pancreatic DuctalCarcinoma, PapillaryDiagnosis, DifferentialEndosonographyFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedPancreatectomyPancreatic NeoplasmsPrognosisRetrospective StudiesSurvival RateTime FactorsTomography, X-Ray ComputedUnited StatesConceptsIntraductal papillary mucinous neoplasmInternational consensus guidelinesMalignant intraductal papillary mucinous neoplasmPapillary mucinous neoplasmConsensus guidelinesMucinous neoplasmsInvasive cancerMain duct intraductal papillary mucinous neoplasmPancreatic intraductal papillary mucinous neoplasmsPercent of patientsSingle-center reviewHigh-grade dysplasiaMayo criteriaWorse survivalPatient groupFemale sexSingle institutionMayo ClinicLower riskPatientsMultivariate analysisCancerResectionMain ductNeoplasms
2009
Evolving Preoperative Evaluation of Patients with Pancreatic Cancer: Does Laparoscopy Have a Role in the Current Era?
Mayo S, Austin D, Sheppard B, Mori M, Shipley D, Billingsley K. Evolving Preoperative Evaluation of Patients with Pancreatic Cancer: Does Laparoscopy Have a Role in the Current Era? Journal Of The American College Of Surgeons 2009, 208: 87-95. PMID: 19228509, DOI: 10.1016/j.jamcollsurg.2008.10.014.Peer-Reviewed Original ResearchConceptsPancreatic adenocarcinomaDiagnostic laparoscopyMetastatic diseaseSurgical explorationEndoscopic ultrasonographyDual-phase CT scanMultivariate logistic regression modelCornerstone of stagingPreoperative weight lossMedical record reviewSubset of patientsPopulation-based studyPancreatic cancer patientsState Cancer RegistrySound clinical approachCurrent imaging modalitiesCombination of CTCurrent staging techniquesLogistic regression modelsCurative intentPotential resectabilityResectable patientsLaparoscopic stagingPreoperative evaluationPrimary outcome
2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Whitehead R, Rankin C, Hoff P, Gold P, Billingsley K, Chapman R, Wong L, Ward J, Abbruzzese J, Blanke C. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Investigational New Drugs 2008, 27: 469. PMID: 18941712, PMCID: PMC3024913, DOI: 10.1007/s10637-008-9190-8.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerColorectal cancerPerformance statusSouthwest Oncology Group studyAdequate bone marrowCombination of romidepsinPrior chemotherapy regimenPrior chemotherapy regimensSignificant cardiac diseaseHuman tumor xenograft modelsAdvanced colorectal cancerPhase II trialColorectal cancer patientsGroup of patientsTreatment of patientsTumor growth inhibitionTumor xenograft modelHistone deacetylase inhibitorsEligible patientsPrior chemotherapyPrior regimensStable diseaseAdvanced diseaseChemotherapy regimenChemotherapy regimensImage of the Month—Quiz Case
Mayo S, Huang H, Dobos N, Billingsley K. Image of the Month—Quiz Case. JAMA Surgery 2008, 143: 1017-1017. PMID: 18936384, DOI: 10.1001/archsurg.143.10.1017.Peer-Reviewed Original ResearchDiagnostic Laparoscopy for Patients with Potentially Resectable Pancreatic Adenocarcinoma: Is It Cost-Effective in the Current Era?
Enestvedt C, Mayo S, Diggs B, Mori M, Austin D, Shipley D, Sheppard B, Billingsley K. Diagnostic Laparoscopy for Patients with Potentially Resectable Pancreatic Adenocarcinoma: Is It Cost-Effective in the Current Era? Journal Of Gastrointestinal Surgery 2008, 12: 1177-1184. PMID: 18470572, DOI: 10.1007/s11605-008-0514-y.Peer-Reviewed Original ResearchConceptsDiagnostic laparoscopyPancreatic cancerPancreatic adenocarcinomaUtilization of laparoscopyResectable pancreatic cancerResectable pancreatic adenocarcinomaPancreatic cancer databaseUse of laparoscopyState Cancer RegistryMedical record dataBiliary bypassPreoperative laparoscopyResectable patientsUnderwent laparoscopyUnresectable diseaseLaparoscopic explorationPeritoneal metastasisCancer RegistryStaging modalitiesCancer DatabaseAverage hospitalLaparoscopyMedicare dataPhysician chargesPatients
2006
Complications and Antireflux Medication Use After Antireflux Surgery
Dominitz J, Dire C, Billingsley K, Todd–Stenberg J. Complications and Antireflux Medication Use After Antireflux Surgery. Clinical Gastroenterology And Hepatology 2006, 4: 299-305. PMID: 16527692, DOI: 10.1016/j.cgh.2005.12.019.Peer-Reviewed Original ResearchConceptsAntireflux medication useAntireflux surgeryMedication useAntireflux medicationVeterans Affairs administrative databasesPredictors of complicationsGastroesophageal reflux diseaseMore outpatient visitsSurgical mortality rateHealth care useH2-receptor antagonistsPostoperative complicationsPromotility agentsReflux diseasePharmacy recordsOutpatient visitsEsophageal cancerReceptor antagonistCare useAdministrative databasesMultiple prescriptionsComplicationsPatientsMortality rateSurgery
2004
Racial Disparities in Rectal Cancer Treatment: A Population-Based Analysis
Morris A, Billingsley K, Baxter N, Baldwin L. Racial Disparities in Rectal Cancer Treatment: A Population-Based Analysis. JAMA Surgery 2004, 139: 151-155. PMID: 14769572, DOI: 10.1001/archsurg.139.2.151.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overBlack PeopleCohort StudiesColectomyConfidence IntervalsCross-Sectional StudiesFemaleHealth Care SurveysHumansIncidenceLogistic ModelsMaleMiddle AgedNeoplasm StagingOdds RatioPostoperative ComplicationsProbabilityRectal NeoplasmsRisk FactorsSEER ProgramSex FactorsSocioeconomic FactorsSurvival AnalysisUnited StatesWhite PeopleConceptsRectal cancer patientsRectal cancerCancer patientsRadiation therapyCross-sectional cohort studyRadiation treatmentRacial disparitiesEnd Results (SEER) databaseSphincter-sparing proceduresRectal cancer treatmentAdvanced disease stagePopulation-based dataDelivery of careSignificant racial disparitiesAdvanced diseaseAggressive screeningCohort studySurgical therapyPelvic cancerSurveillance EpidemiologyResults databaseTreatment disparitiesDisease stageMinority patientsSurgical care
2003
Outcome After Pancreaticoduodenectomy for Periampullary Cancer: An Analysis from the Veterans Affairs National Surgical Quality Improvement Program
Billingsley K, Hur K, Henderson W, Daley J, Khuri S, Bell R. Outcome After Pancreaticoduodenectomy for Periampullary Cancer: An Analysis from the Veterans Affairs National Surgical Quality Improvement Program. Journal Of Gastrointestinal Surgery 2003, 7: 484-491. PMID: 12763405, DOI: 10.1016/s1091-255x(03)00067-2.Peer-Reviewed Original ResearchConceptsNational Surgical Quality Improvement ProgramSurgical Quality Improvement ProgramVeterans Affairs Healthcare SystemQuality Improvement ProgramPeriampullary cancerAdverse outcomesRisk factorsVeterans Affairs National Surgical Quality Improvement ProgramVA National Surgical Quality Improvement ProgramPre-defined complicationsPostoperative mortality ratePreoperative risk factorsPreoperative serum albuminMain outcome measuresRisk-adjusted comparisonsDifferent health care systemsVA Medical CenterLogistic regression analysisHealth care systemPancreaticoduodenectomy outcomesPostoperative mortalityAnesthesiologists classificationPostoperative deathsSeptic complicationsIntraoperative variables